情妇

China reports 522,000 new COVID-19 cases, one death in July amid fluctuating upward trend_我的网站

佩小姐的奇幻城堡

A | 每经编辑：叶峰当前全球科技产业正处于人工智能算力需求爆发与外部科技封锁边际趋严的宏观交汇点。

Photo： VCG
China reported 522,000 newly confirmed COVID-19 cases in July, including 487 severe cases and one related death with cases showing a fluctuating upward trend, China's national disease control authority said.
The current uptick in infections represents another regular cyclical wave, with its severity comparable to surges seen in the past two years. The upward growth curve has slowed markedly, and the country is now on the plateau phase of this epidemic peak, said the Chinese Center for Disease Control and Prevention (Chinese CDC) on Thursday.
All tested infection samples were confirmed to be the Omicron variant, with the NB.1.8.1 strain and its sublineages accounting for the majority of circulating cases, the Chinese CDC said.
A Beijing-based respiratory disease specialist told the Global Times that waning population immunity, continued virus mutations that weaken existing antibody protection, and increased summer travel have contributed to the recent modest rise in infections. However, there is no evidence that the virus has become more pathogenic. Nationwide infections appear to be nearing their peak and case numbers may begin falling in late August.
A screenshot from Chinese CDC report on new COVID-19 cases in July nationwide

A screenshot from Chinese CDC report on new COVID-19 cases in July nationwide
According to sentinel hospital surveillance data, from June 29-July 5 to July 27-August 2, the proportion of influenza-like illness among all outpatient and emergency visits at China's 1,041 COVID-19 and influenza sentinel hospitals edged up with slight fluctuations, standing at 4.3 percent, 4.4 percent, 4.5 percent, 4.4 percent and 4.5 percent, respectively.
During the same period, the COVID-19 positivity rate among patients with influenza-like illness in outpatient and emergency departments rose for consecutive weeks.
Several factors drove the fluctuating rise in COVID-19 cases in July. Population immunity has waned, as more than six months have passed since the last major wave of infections for most people, while continued SARS-CoV-2 mutations have reduced the protection provided by existing antibodies, Li Tongzeng, a respiratory disease medic from Beijing You An Hospital to the Capital Medical University, told the Global Times on Friday.
These factors, combined with increased travel and population mobility during the summer vacation, contributed to the recent small-scale surge. Based on patterns observed in recent years, COVID-19 infections tend to rise every six to eight months as population immunity declines, said Li.
The expert noted that while the virus continues to mutate, there is no evidence that it has become more pathogenic. Clinical data show that most patients develop only mild symptoms, with very few progressing to pneumonia or requiring hospitalization.
The Chinese CDC noted on Thursday that since COVID-19 was reclassified as a Category B infectious disease under Category B management, it has evolved into a prevalent, recurring respiratory infectious disease in China, with one to two epidemic fluctuations occurring nationwide each year.
Li also noted that residual immunity from previous infections also helps reduce disease severity, with most reinfections presenting as mild upper respiratory symptoms that resolve within about a week. The single COVID-related death reported nationwide in July further indicates that the current fatality rate remains very low.
Judging from historical epidemic patterns and current case growth trajectories, national infection figures may begin to decline in late August. Nationwide case numbers are now nearly at their peak, with declines already observed in some regions, said Li.
The Chinese CDC also said on Thursday that surveillance had not detected any variants posing major public health risks, nor had the current wave caused notable disruptions to the healthcare system.
The public is advised to take appropriate protective measures, including wearing masks when necessary, maintaining good personal hygiene, adopting healthy lifestyles and getting vaccinated as recommended.
。这一宏观热点重塑了半导体产业链的供需结构（即产品供应能力与市场实际需求之间的匹配关系）与定价模型（即通过预期盈利和风险溢价来评估资产价值的数学框架）。在此理论框架下，国内半导体产业自主可控进程加速，芯片设计环节作为直接对接下游应用需求的核心，迎来了产业价值重估。科创芯片设计ETF天弘(589070)作为映射该逻辑的资产配置工具，通过紧密跟踪相关指数，为投资者提供了参与硬科技龙头估值修复的标准化解决方案。 AI算力周期: 算力需求指数级增长对芯片设计环节的拉动效应 1. 华泰证券(2026-06-23)研报显示，晶圆行业正进入由AI需求驱动的新一轮上行周期，先进制程因AI算力拉动而结构性短缺，支撑价格中枢多年上移，为芯片设计环节的定价模型（即通过预期盈利和风险溢价来评估资产价值的数学框架）提供了基本面支撑。 2. 在算力军备竞赛催化下，AI对先进逻辑的需求曲线被整体抬升，台积电披露AI晶圆需求2022至2026年增长约11倍，这一量化指标直接带动国内算力芯片设计企业的订单增长与产品迭代。 3. 根据SEMI预测数据，2026年全球半导体设备销售额预计将增长23.2%达到1659亿美元，下游晶圆厂大规模扩产预期为上游芯片设计企业提供了明确的业绩兑现指引。但需指出的是，全球贸易摩擦加剧可能导致供应链波动风险，从而对芯片设计企业的先进制程流片进度造成不确定性影响。国产替代加速: 政策引导自主可控进程 1. 中信证券(2026-07-14)分析指出，半导体设备、AI算力芯片等领域的国产化率提升空间广阔，为芯片设计企业提供了战略级的市场增量。 2. 资金端有定向宽松工具持续输送低成本资金，规模万亿级的科技创新再贷款已全面落地，专门面向半导体等行业提供低息融资，有效减轻芯片设计企业长期研发扩产带来的资金压力。

B | 3. 从历史复盘来看，2020至2022年代表公司ASP（平均销售单价）普遍上涨约25%至59%，各家毛利率全面改善，若本轮国产替代带来的涨价兑现，相关企业的盈利弹性在逻辑上具备价格弹性。但需指出的是，半导体经营仍面临地缘政治与环保合规的不确定性，国产替代进度可能受制于上游设备材料的交付周期。

C | 产业趋势重估: 硬科技龙头在供需紧平衡下的估值修复 1. 东吴证券(2026-07-01)分析指出，AI需求爆发正将光芯片推向前所未有的供需紧平衡状态（即产品供应能力与市场实际需求之间的极度紧缺匹配关系），100G EML 2026年产能爬坡有望填补全球供需缺口，带动相关设计企业深度受益行业景气上行。 2. 存储芯片等有业绩兑现预期的细分方向驱动市场主线，长鑫科技IPO推进以及国产算力链业绩开始兑现，为科创芯片板块的估值修复提供了微观企业盈利的基础。

D | 3. 2026年长江存储与长鑫存储合计新增10至12万片/月产能，投资总额有望达155至180亿美元，资本开支扩张直接映射为芯片设计环节的产业景气度上行。但需指出的是，行业内部竞争加剧可能导致价格战，从而削弱设计环节的盈利空间，且短期市场波动风险加剧或带来情绪面冲击。

E | 科创芯片设计ETF天弘(589070)所映射的指数编制逻辑，有效剔除了传统制造业的杂质，精准聚焦于芯片设计这一核心主线，符合自主可控周期下的产业演进方向。作为标准化解决方案，该产品有望迎来估值修复，但在应用过程中需警惕短期市场波动风险与地缘政治的不确定性。整体而言，其作为资产配置工具的功能定位，清晰映射了AI算力与国产替代双重产业趋势的宏观逻辑，为投资者提供了参与硬科技龙头价值重估的高效工具。产品亮点：科创芯片设计ETF天弘（589070）核心优势科创芯片设计ETF天弘（589070）换手率长期同类领先，流动性较好。该产品管理费率0.50%、托管费率0.10%，是低费率进行该赛道配置的重要工具之一。该基金近十个交易日日均成交额达1.92亿元，日均换手率为10.95%。该产品流动性好，可充分满足投资者日常交易需求。